Transfusion medicine reviews
-
Randomized Controlled Trial Multicenter Study
The age of red blood cells in premature infants (ARIPI) randomized controlled trial: study design.
Despite recent trends in decreasing transfusion thresholds and the development of technologies designed to avoid allogeneic exposure, allogeneic red blood cell (RBC) transfusions remain an important supportive and life-saving measure for neonatal intensive care patients experiencing illness and anemia. Reluctantly, a number of laboratory and observational studies have indicated that the amount of time RBCs are stored can affect oxygen delivery to tissues. Consequently, older RBCs may result in higher rates of organ dysfunction, nosocomial infection, and lengths of stay. ⋯ Assuming a 15% absolute risk reduction with the use of RBCs stored 7 days or less, our estimated total sample size required will be 450 (225 patients per treatment arm). The Age of Red Blood Cells in Premature Infants (ARIPI) trial is registered at the US National Institutes of Health (ClinicalTrials.gov) no. NCT00326924 and current controlled trials ISRCTN65939658.
-
Blood transfusion remains one of the commonest interventions carried out upon individuals undergoing cardiac surgery. Despite this, the scientific rationale on which to base this decision is limited. Currently, hemoglobin concentration is often used as the sole guide as to when a transfusion may be required. ⋯ Furthermore, oxygen requirements during the initial perioperative phase are reduced because of the effect of general anesthesia and hypothermia during cardiopulmonary bypass. When deciding to transfuse, consideration should be given to red cell volume, circulatory status, and oxygen requirement. It is possible that such an all-encompassing approach would reduce the incidence of unnecessary, and potentially counterproductive, red cell transfusion in cardiac surgery.